Regulation of multidrug resistance by microRNAs in anti-cancer therapy

Fojo, 1987, Multidrug resistance in ovarian cancer, Cancer, 60, S2075, 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F Gong, 2012, Microparticles and their emerging role in cancer multidrug resistance, Cancer Treat Rev, 38, 226, 10.1016/j.ctrv.2011.06.005 Baguley, 2010, Multidrug resistance in cancer, Methods Mol Biol, 596, 1, 10.1007/978-1-60761-416-6_1 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706 Szakács, 2006, Targeting multidrug resistance in cancer, Nat Rev Drug Discov, 5, 219, 10.1038/nrd1984 Gottesman, 2006, The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research, FEBS Lett, 580, 998, 10.1016/j.febslet.2005.12.060 Schinkel, 2003, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, Adv Drug Deliv Rev, 55, 3, 10.1016/S0169-409X(02)00169-2 Gillet, 2007, Chemotherapy-induced resistance by ATP-binding cassette transporter genes, Biochim Biophys Acta, 1775, 237 Consortium, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028 Piecuch, 2014, proteins involved in multidrug resistance, Cell Mol Biol Lett, 19, 1, 10.2478/s11658-013-0111-2 Huang, 2014, The accumulation and efflux of lead partly depend on ATP-dependent efflux pump-multidrug resistance protein 1 and glutathione in testis Sertoli cells, Toxicol Lett, 226, 277, 10.1016/j.toxlet.2014.02.017 Sodani, 2012, Multidrug resistance associated proteins in multidrug resistance, Chin J Cancer, 31, 58, 10.5732/cjc.011.10329 Tiwari, 2011, Revisiting the ABCs of multidrug resistance in cancer chemotherapy, Curr Pharm Biotechnol, 12, 570, 10.2174/138920111795164048 Assaraf, 2003, Loss of multidrug resistance protein 1 (MRP1) expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells, J Biol Chem, 278, 6680, 10.1074/jbc.M209186200 Wang, 2014, Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2, Oncotarget, 5, 4529, 10.18632/oncotarget.2102 Mao, 2005, Role of the breast cancer resistance protein (ABCG2) in drug transport, AAPS J, 7, E118, 10.1208/aapsj070112 Sun, 2012, Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance, Anticancer Drugs, 23, 865, 10.1097/CAD.0b013e328354a196 Kastan, 1995, P53, cell cycle control and apoptosis: implications for cancer, Cancer Metastasis Rev, 14, 3, 10.1007/BF00690207 Turzanski, 2000, Eur J Cancer, 36, 270, 10.1016/S0959-8049(99)00286-5 Milicevic, 2014, Mutant p53 protein expression and antioxidant status deficiency in breast cancer, EXCLI J, 13, 691 Oshika, 1998, Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer, Mod Pathol, 11, 1059 Pommier, 2004, Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks, Oncogene, 23, 2934, 10.1038/sj.onc.1207515 Kaufmann, 2000, Induction of apoptosis by cancer chemotherapy, Exp Cell Res, 256, 42, 10.1006/excr.2000.4838 Wilson, 2009, Anti-apoptotic mechanisms of drug resistance in cancer, Curr Cancer Drug Targets, 9, 307, 10.2174/156800909788166547 Dole, 1994, Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma, Cancer Res, 54, 3253 Youle, 2008, The BCL-2 protein family: opposing activities that mediate cell death, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 Rong, 2008, Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis, Annu Rev Physiol, 70, 73, 10.1146/annurev.physiol.70.021507.105852 Ying, 2015, Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers, Oncol Lett, 9, 1759, 10.3892/ol.2015.2950 Bentires-Alj, 2003, NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells, Oncogene, 22, 90, 10.1038/sj.onc.1206056 Huang, 2009, Induction of Akt activity by chemotherapy confers acquired resistance, J Formos Med Assoc, 108, 180, 10.1016/S0929-6646(09)60051-6 Levine, 2008, Autophagy in the pathogenesis of disease, Cell, 132, 27, 10.1016/j.cell.2007.12.018 Yang, 2010, Eaten alive: a history of macroautophagy, Nat Cell Biol, 12, 814, 10.1038/ncb0910-814 Wen, 2015, Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis, Breast Cancer Res Treat, 149, 619, 10.1007/s10549-015-3283-9 Yu, 2014, Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance, Cancer Lett, 355, 34, 10.1016/j.canlet.2014.09.020 Chen, 2014, The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells, Int J Mol Med, 34, 276, 10.3892/ijmm.2014.1772 Pan, 2015, Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin, Genet Mol Res, 14, 5621, 10.4238/2015.May.25.14 Kumar, 2015, Targeting autophagy to overcome drug resistance in cancer therapy, Future Med Chem, 7, 1535, 10.4155/fmc.15.88 Chen, 2016, Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib, Tumour Biol, 37, 2321, 10.1007/s13277-015-3800-9 O׳Donovan, 2011, Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics, Autophagy, 7, 509, 10.4161/auto.7.5.15066 Henson, 2006, Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy, Cell Signal, 18, 2089, 10.1016/j.cellsig.2006.05.015 Ghadimi, 2012, Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors, Mol Cancer Ther, 11, 1758, 10.1158/1535-7163.MCT-12-0015 Stanton, 2013, Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance, Cancer Res, 73, 160, 10.1158/0008-5472.CAN-11-3635 Paillas, 2012, MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy, Autophagy, 8, 1098, 10.4161/auto.20268 Hennigan, 2013, The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38SAPK pathway, Oncogene, 32, 1135, 10.1038/onc.2012.135 Crommentuyn, 1998, In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide, Cancer Treat Rev, 24, 345, 10.1016/S0305-7372(98)90057-3 Kivisto, 1995, The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions, Br J Clin Pharmacol, 40, 523, 10.1111/j.1365-2125.1995.tb05796.x Vassal, 1998, Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology, Biochimie, 80, 271, 10.1016/S0300-9084(98)80009-6 Patterson, 2002, Tumour cytochrome P450 and drug activation, Curr Pharm Des, 8, 1335, 10.2174/1381612023394502 Mwinyi, 2014, Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy, Cancer Chemother Pharmacol, 73, 1181, 10.1007/s00280-014-2453-5 Peters, 2002, Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism, Biochim Biophys Acta, 1587, 194, 10.1016/S0925-4439(02)00082-0 Nakamura, 2010, Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma, Int J Oncol, 37, 845 Nitiss, 2009, Targeting DNA topoisomerase II in cancer chemotherapy, Nat Rev Cancer, 9, 338, 10.1038/nrc2607 Ganapathi, 2013, Mechanisms regulating resistance to inhibitors of topoisomerase II, Front Pharmacol, 4, 89, 10.3389/fphar.2013.00089 Geng, 2013, The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer, Diagn Pathol, 8, 198, 10.1186/1746-1596-8-198 Wilson, 2006, Chemoresistance in solid tumours, Ann Oncol, 17 Suppl 10, x315, 10.1093/annonc/mdl280 Allen, 1998, Implementation of new technologies in cytotechnology education, Cancer, 84, 324, 10.1002/(SICI)1097-0142(19981225)84:6<324::AID-CNCR2>3.0.CO;2-5 Ribic, 2003, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 349, 247, 10.1056/NEJMoa022289 Marullo, 2013, Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions, PLoS One, 8, e81162, 10.1371/journal.pone.0081162 Fan, 2014, Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling, Oncotarget, 5, 2853, 10.18632/oncotarget.1854 Lin, 2012, Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells, PLoS One, 7, e38706, 10.1371/journal.pone.0038706 Liu, 2015, Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome, J Cell Mol Med, 19, 1949, 10.1111/jcmm.12570 Acharya, 2010, Redox regulation in cancer: a double-edged sword with therapeutic potential, Oxid Med Cell Longev, 3, 23, 10.4161/oxim.3.1.10095 Liu, 2016, Cancer drug resistance: redox resetting renders a way, Oncotarget Traverso, 2013, Role of glutathione in cancer progression and chemoresistance, Oxid Med Cell Longev, 2013, 972913, 10.1155/2013/972913 Pompella, 2007, γ-glutamyltransferase, redox regulation and cancer drug resistance, Curr Opin Pharmacol, 7, 360, 10.1016/j.coph.2007.04.004 Schnekenburger, 2014, Regulation of epigenetic traits of the glutathione S-transferase P1 gene: from detoxification toward cancer prevention and diagnosis, Front Pharmacol, 5, 170, 10.3389/fphar.2014.00170 Jardim, 2013, Glutathione and glutathione peroxidase expression in breast cancer: an immunohistochemical and molecular study, Oncol Rep, 30, 1119, 10.3892/or.2013.2540 Backos, 2012, The role of glutathione in brain tumor drug resistance, Biochem Pharmacol, 83, 1005, 10.1016/j.bcp.2011.11.016 Singh, 2015, Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death, Cancer Chemother Pharmacol, 75, 1, 10.1007/s00280-014-2566-x Beeghly, 2006, Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival, Gynecol Oncol, 100, 330, 10.1016/j.ygyno.2005.08.035 Ge, 2013, The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China, PLoS One, 8, e67589, 10.1371/journal.pone.0067589 Kap, 2014, Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin, Pharmacogenet Genom, 24, 340, 10.1097/FPC.0000000000000059 Townsend, 2003, The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, 22, 7369, 10.1038/sj.onc.1206940 Ramsay, 2014, S-conjugates as prodrugs to target drug-resistant tumors, Front Pharmacol, 5, 181, 10.3389/fphar.2014.00181 Rutnam, 2013, miRNAs regulate expression and function of extracellular matrix molecules, Matrix Biol, 32, 74, 10.1016/j.matbio.2012.11.003 Vasudevan, 2007, Switching from repression to activation: microRNAs can up-regulate translation, Science, 318, 1931, 10.1126/science.1149460 Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y Kozomara, 2011, miRBase: integrating microRNA annotation and deep-sequencing data, Nucleic Acids Res, 39, D152, 10.1093/nar/gkq1027 Spizzo, 2012, Long non-coding RNAs and cancer: a new frontier of translational research, Oncogene, 31, 4577, 10.1038/onc.2011.621 Mendell, 2012, MicroRNAs in stress signaling and human disease, Cell, 148, 1172, 10.1016/j.cell.2012.02.005 Esteller, 2011, Non-coding RNAs in human disease, Nat Rev Genet, 12, 861, 10.1038/nrg3074 Jiang, 2009, miR2Disease: a manually curated database for microRNA deregulation in human disease, Nucleic Acids Res, 37, D98, 10.1093/nar/gkn714 Ambros, 2003, MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing, Cell, 113, 673, 10.1016/S0092-8674(03)00428-8 Croce, 2009, Causes and consequences of microRNA dysregulation in cancer, Nat Rev Genet, 10, 704, 10.1038/nrg2634 Liang, 2011, Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy, Acta Pharmacol Sin, 32, 1311, 10.1038/aps.2011.103 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci USA, 105, 10513, 10.1073/pnas.0804549105 Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 Zhu, 2014, Different miRNA expression profiles between human breast cancer tumors and serum, Front Genet, 5, 149, 10.3389/fgene.2014.00149 Fojo, 2007, Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs, Drug Resist Updat, 10, 59, 10.1016/j.drup.2007.02.002 Blower, 2008, MicroRNAs modulate the chemosensitivity of tumor cells, Mol Cancer Ther, 7, 1, 10.1158/1535-7163.MCT-07-0573 Wang, 2015, The role of microRNAs in the chemoresistance of breast cancer, Drug Dev Res, 76, 368, 10.1002/ddr.21275 Zhu, 2008, Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells, Biochem Pharmacol, 76, 582, 10.1016/j.bcp.2008.06.007 Li, 2010, miR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells, Gynecol Oncol, 119, 125, 10.1016/j.ygyno.2010.06.004 Kovalchuk, 2008, Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin, Mol Cancer Ther, 7, 2152, 10.1158/1535-7163.MCT-08-0021 Feng, 2011, Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia, J Cell Mol Med, 15, 2164, 10.1111/j.1582-4934.2010.01213.x Chen, 2013, MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells, Cell Signal, 25, 2693, 10.1016/j.cellsig.2013.08.032 Zhao, 2010, miR-138 might reverse multidrug resistance of leukemia cells, Leuk Res, 34, 1078, 10.1016/j.leukres.2009.10.002 Bao, 2012, Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298, Am J Pathol, 180, 2490, 10.1016/j.ajpath.2012.02.024 Xu, 2013, Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance, PLoS One, 8, e82062, 10.1371/journal.pone.0082062 Yang, 2013, miR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells, Exp Biol Med, 238, 1024, 10.1177/1535370213497321 Munoz, 2013, Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity, Mol Ther Nucleic Acids, 2, e126, 10.1038/mtna.2013.60 Lin, 2008, miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines, Biochem Biophys Res Commun, 375, 315, 10.1016/j.bbrc.2008.07.154 Wu, 2016, MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1, Tumour Biol, 37, 10499, 10.1007/s13277-016-4944-y Shang, 2014, miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1, Oncogene, 33, 3267, 10.1038/onc.2013.297 Shang, 2016, The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer, Oncotarget, 7, 538, 10.18632/oncotarget.6374 To, 2008, Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line, Mol Cell Biol, 28, 5147, 10.1128/MCB.00331-08 Pan, 2009, MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells, Mol Pharmacol, 75, 1374, 10.1124/mol.108.054163 Li, 2010, Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance, Med Sci Monit, 16, HY27 Li, 2011, Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells, Biochem Pharmacol, 81, 783, 10.1016/j.bcp.2010.12.018 Turrini, 2012, MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression, Pharmacogenet Genom, 22, 198, 10.1097/FPC.0b013e328350012b Jiao, 2013, miR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2), Breast Cancer Res Treat, 139, 717, 10.1007/s10549-013-2607-x Ma, 2013, miR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2), Cancer Lett, 339, 107, 10.1016/j.canlet.2013.07.016 Liang, 2010, Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1, Biochem Pharmacol, 79, 817, 10.1016/j.bcp.2009.10.017 Pan, 2013, Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1, Drug Metab Dispos, 41, 1744, 10.1124/dmd.113.052092 Li, 2015, Elevated microRNA-23a expression enhances the chemoresistance of colorectal cancer cells with microsatellite instability to 5-fluorouracil by directly targeting ABCF1, Curr Protein Pept Sci, 16, 301, 10.2174/138920371604150429153309 Wu, 2016, BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10, Cancer Lett, 371, 125, 10.1016/j.canlet.2015.11.031 Wu, 2014, Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters, Oncotarget, 5, 11552, 10.18632/oncotarget.2594 Wang, 2015, The effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines, PLoS One, 10, e0125473, 10.1371/journal.pone.0125473 Iida, 2013, miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor, Cancer Cell Int, 13, 21, 10.1186/1475-2867-13-21 Liang, 2016, MicroRNA-140 regulates cell growth and invasion in pancreatic duct adenocarcinoma by targeting iASPP, Acta Biochim Biophys Sin, 48, 174, 10.1093/abbs/gmv127 Fornari, 2009, miR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells, Cancer Res, 69, 5761, 10.1158/0008-5472.CAN-08-4797 Fujita, 2008, Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells, Biochem Biophys Res Commun, 377, 114, 10.1016/j.bbrc.2008.09.086 Lodygin, 2008, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer, Cell Cycle, 7, 2591, 10.4161/cc.7.16.6533 Fan, 2014, miR-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells, PLoS One, 9, e108514, 10.1371/journal.pone.0108514 Chakraborty, 2014, Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells, FEBS Lett, 588, 549, 10.1016/j.febslet.2013.11.040 Xia, 2008, miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells, Int J Cancer, 123, 372, 10.1002/ijc.23501 Cittelly, 2010, Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors, Carcinogenesis, 31, 2049, 10.1093/carcin/bgq192 Dong, 2011, Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells, Arch Med Res, 42, 8, 10.1016/j.arcmed.2011.01.006 Zhu, 2012, miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2, Med Oncol, 29, 384, 10.1007/s12032-010-9797-4 Zhu, 2012, miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP, Cancer Chemother Pharmacol, 69, 723, 10.1007/s00280-011-1752-3 Xu, 2013, miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells, Mol Carcinog, 52, 70, 10.1002/mc.21832 Wang, 2013, miR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells, FEBS Lett, 587, 488, 10.1016/j.febslet.2013.01.016 Qu, 2015, MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA, J Cell Physiol, 230, 535, 10.1002/jcp.24366 Verdoodt, 2013, MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer, Int J Oncol, 43, 307, 10.3892/ijo.2013.1915 Chiyomaru, 2013, Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer, PLoS One, 8, e58929, 10.1371/journal.pone.0058929 He, 2016, MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1, Mol Med Rep, 13, 1923, 10.3892/mmr.2015.4727 Romano, 2012, miR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation, Proc Natl Acad Sci U S A, 109, 16570, 10.1073/pnas.1207917109 Hamada, 2014, miR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX, Cell Signal, 26, 179, 10.1016/j.cellsig.2013.11.003 Quintavalle, 2013, Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells, Oncogene, 32, 4001, 10.1038/onc.2012.410 Yang, 2013, Epstein-barr virus_encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L, PLoS One, 8, e78355, 10.1371/journal.pone.0078355 Meng, 2007, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, Gastroenterology, 133, 647, 10.1053/j.gastro.2007.05.022 Yang, 2013, miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN, Toxicology, 306, 162, 10.1016/j.tox.2013.02.014 Li, 2011, Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells, Mol Cell Biochem, 357, 31, 10.1007/s11010-011-0872-8 Zhao, 2013, MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma, PLoS One, 8, e53906, 10.1371/journal.pone.0053906 Wang, 2012, MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines, Asian Pac J Cancer Prev, 13, 255, 10.7314/APJCP.2012.13.1.255 Wang, 2013, MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN, Biochem Biophys Res Commun, 434, 688, 10.1016/j.bbrc.2013.04.010 Fang, 2014, MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression, Oncotarget, 5, 2974, 10.18632/oncotarget.1614 Zeng, 2016, miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells, J Cell Mol Med, 20, 559, 10.1111/jcmm.12760 Zhu, 2009, Regulation of autophagy by a beclin 1–targeted microRNA, miR–30a, in cancer cells, Autophagy, 5, 816, 10.4161/auto.9064 Yu, 2012, microRNA 30A promotes autophagy in response to cancer therapy, Autophagy, 8, 853, 10.4161/auto.20053 Yu, 2012, Targeting microRNA-30a–mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells, Leukemia, 26, 1752, 10.1038/leu.2012.65 Xu, 2016, MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1–mediated autophagy, Oncol Rep, 35, 1757, 10.3892/or.2015.4497 Zheng, 2015, miRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib, Biochem Biophys Res Commun, 459, 234, 10.1016/j.bbrc.2015.02.084 Zhang, 2014, Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin, Biochem Pharmacol, 87, 562, 10.1016/j.bcp.2013.12.004 Sümbül, 2014, miR-204-5p expression in colorectal cancer: an autophagy-associated gene, Tumour Biol, 35, 12713, 10.1007/s13277-014-2596-3 Xiao, 2011, miR-204 regulates cardiomyocyte autophagy induced by ischemia–reperfusion through LC3-II, J Biomed Sci, 18, 35, 10.1186/1423-0127-18-35 Chatterjee, 2015, miR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis, Cell Signal, 27, 189, 10.1016/j.cellsig.2014.11.023 Chen, 2014, miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy, Exp Ther Med, 8, 527, 10.3892/etm.2014.1752 Pan, 2015, miR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma, Oncotarget, 6, 32805, 10.18632/oncotarget.5352 Huang, 2015, miR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin, Cancer Biol Ther, 16, 941, 10.1080/15384047.2015.1040963 Zhao, 2016, miR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin, Gene, 576, 828, 10.1016/j.gene.2015.11.013 Tsuchiya, 2006, MicroRNA regulates the expression of human cytochrome P450 1B1, Cancer Res, 66, 9090, 10.1158/0008-5472.CAN-06-1403 Martinez, 2008, CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance, Br J Cancer, 98, 564, 10.1038/sj.bjc.6604195 Mu, 2015, miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression, Cell Res, 25, 477, 10.1038/cr.2015.23 Choi, 2012, CYP1A1 is a target of miR-892a-mediated post-transcriptional repression, Int J Oncol, 41, 331 Chen, 2012, Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2, PLoS One, 7, e39197, 10.1371/journal.pone.0039197 Takagi, 2008, Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4, J Biol Chem, 283, 9674, 10.1074/jbc.M709382200 Boni, 2010, miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation, Mol Cancer Ther, 9, 2265, 10.1158/1535-7163.MCT-10-0061 Hirota, 2012, Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues, Lung Cancer, 77, 16, 10.1016/j.lungcan.2011.12.018 Maftouh, 2014, miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells, Nucleosides Nucleotides Nucleic Acids, 33, 384, 10.1080/15257770.2014.891741 Bhutia, 2013, Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein, PLoS One, 8, e53436, 10.1371/journal.pone.0053436 Valeri, 2010, MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2), Proc Natl Acad Sci U S A, 107, 21098, 10.1073/pnas.1015541107 Valeri, 2010, Modulation of mismatch repair and genomic stability by miR-155, Proc Natl Acad Sci U S A, 107, 6982, 10.1073/pnas.1002472107 Moskwa, 2011, miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors, Mol Cell, 41, 210, 10.1016/j.molcel.2010.12.005 Sun, 2013, miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition, J Natl Cancer Inst, 105, 1750, 10.1093/jnci/djt302 Mikhed, 2015, Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage/repair, Redox Biol, 5, 275, 10.1016/j.redox.2015.05.008 Ouyang, 2015, The use of microRNAs to modulate redox and immune response to stroke, Antioxid Redox Signal, 22, 187, 10.1089/ars.2013.5757 Drayton, 2014, Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11, Clin Cancer Res, 20, 1990, 10.1158/1078-0432.CCR-13-2805 Zhang, 2012, miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1, Lung Cancer, 77, 488, 10.1016/j.lungcan.2012.05.107 Chen, 2015, MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs, Drug Des Devel Ther, 9, 5225 Yang, 2014, miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2, Anticancer Agents Med Chem, 14, 884, 10.2174/1871520614666140528161318 Feng, 2015, Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells, Int J Clin Exp Pathol, 8, 6107 Penna, 2015, miR-214 as a key hub that controls cancer networks: small player, multiple functions, J Investig Dermatol, 135, 960, 10.1038/jid.2014.479